Zilucoplan

Unassigned

New Medicines

Generalised myasthenia gravis

Information

New molecular entity
Ra Pharmaceuticals
Ra Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Synthetic cyclomimetic complement C5 inhibitor - disrupts the interaction between C5b and C6, interrupting the inflammatory cascade.[2,3]
The incidence ranges from 0.3 to 2.8 per 100,000. It is estimated to affect more than 700,000 people worldwide. The prevalence of MG in the UK is estimated at about 15 per 100,000 population [1].
Generalised myasthenia gravis
Subcutaneous injection